Protocol Ledger

NCT07027020 · Phase III · RECRUITING

Efficacy of Intravesical Oxybutynin in Children With Neurogenic Bladder Dysfunction

Interventional Phase III clinical trial protocol NCT07027020 sponsored by Central Hospital, Nancy, France in Rare Genetic, Women's Health, and Other, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2026-01-15 Enrollment: 60 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT07027020
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)60 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)0 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT07027020
Protocol FieldVerified Registry Value
NCT IdentifierNCT07027020
Consolidated Lead SponsorCentral Hospital, Nancy, France
Therapeutic Condition CohortRare Genetic, Women's Health, and Other
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment60 participants (ESTIMATED)
Registered Start Date2026-01-15
WhyStopped ClassificationNot Stopped

Search related sites and sponsors in the Interactive Directory, explore Rare Genetic, Women's Health, and Other Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI